Many patients with idiopathic pulmonary fibrosis (IPF) who are switching from Esbriet (pirfenidone) to Ofev (nintedanib) discontinue treatment, especially if they are underweight or have anorexia while being treated with Esbriet, a Japanese study says. The findings, “Negative impact of anorexia and weight loss during prior pirfenidone…
Despite Benefits, Many IPF Patients Switching from Esbriet to Ofev Stop Treatment, Possibly Due to Low BMI, Study Says
The pulmonary fibrosis (PF) community is invited to attend the Pulmonary Fibrosis Foundation‘s PFF Summit, which is the largest healthcare meeting on PF, offering data on the latest research. Attendees will get the chance to learn more about the potential of DNA sequencing and targeted therapies to…
We learn the most important lessons in the most difficult times, and I’m grateful to have had opportunities to live those lessons and share them with others. An internet search of popular life lessons showed me the following: It’s not all about you. Your health is your most…
Rare variants in genes that regulate the end regions of chromosomes — called telomeres — are linked with worse survival rates after lung transplant in pulmonary fibrosis (PF) patients, a study suggests. The study, “Lung Transplant Outcomes in Pulmonary Fibrosis Patients with Telomere-Related Gene Variants” was published in the…
Before receiving my official diagnosis of idiopathic pulmonary fibrosis (IPF), I was confident in my knowledge of it. Since it was suggested as a potential diagnosis, I spent many hours researching all facets of the disease. I was amazed by how many people were affected by IPF, yet so…
Treatment with Ofev (nintedanib) can significantly extend the survival of patients with idiopathic pulmonary fibrosis (IPF), an analysis of pooled data from six clinical trials shows. The analyis, conducted by an international research team, was published in the journal BMJ Open Respiratory Research, in an article titled “…
The American Thoracic Society (ATS) Foundation and Boehringer Ingelheim have awarded a physician scientist at Northwestern University this year’s research grant in idiopathic pulmonary fibrosis (IPF). Paul Andrew Reyfman, MD, was the recipient of the $100,000 fellowship, which will help fund his project, “Single Cell Transcriptomic…
Myth 1: If you can’t run with the big dogs, stay on the porch. Truth: In the words of the late great Dr. Martin Luther King Jr., “if you can’t fly then run, if you can’t run then walk, if you can’t walk then crawl, but whatever you do you…
Pliant Therapeutics has successfully completed a Phase 1 clinical study assessing its investigational therapy PLN-74809 for idiopathic pulmonary fibrosis (IPF), with results supporting further clinical development of the compound. PLN-74809 is an oral small molecule that selectively inhibits integrins (signaling receptors) called αVβ6 and αVβ1. Results from earlier preclinical…
Most Canadians will remember where they were when they heard the news of the Humboldt Broncos bus crash on April 6, 2018. The Saskatchewan-based hockey team was traveling to a playoff game when their bus collided with a semitrailer. Of 29 people onboard, 16 died of…
